Virgin Voyages Sets Sights on the Med for Second Ship ‘Valiant Lady’ Launching 3 Exhilarating 7-night Itineraries From Barcelona With Overnights in Ibiza
19.11.2019 17:02:00 EET | Business Wire | Press release
Virgin Voyages, the new lifestyle brand shaking up the travel industry, announced their second ship will be called ‘Valiant Lady’ and that she will sail 7-night Mediterranean itineraries out of Barcelona, Spain when she debuts in May 2021. Bookings for the three feature itineraries, that all offer overnight and late-night stops across some of the hottest destinations in France, Italy and Spain, will open December 19, 2019.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005362/en/
Virgin Voyages Sets Sights on the Med for Second Ship ‘Valiant Lady’ (Graphic: Business Wire)
“We are thrilled to unveil the name of our second ship - Valiant Lady - and to deliver on our commitment to offer travelers a sea change in how they can experience cruising in this fantastic part of the world. Our Sailors will fall in love with the places we go and the moments and memories they will be able to create on our gorgeous ship. After all, there is no better way to sail the seven seas than doing it the Virgin way,” said Tom McAlpin, CEO of Virgin Voyages.
2021 Summers on the Med with a home in Barcelona
Valiant Lady will dock just steps from Las Ramblas at the World Trade Center Barcelona, positioning Sailors as close to the heart of this stunning departure-port-city as possible. This prime location, usually reserved by luxury liners and mega-yachts, gives walking access to the dynamic and diverse neighborhoods of Poble Sec, el Raval, Barri Gotic, Port Vell and the famed urban beach of La Barceloneta. With a weekly Sunday sail away, Sailors will enjoy extra time in Barcelona and be able to take advantage of many different flight options. Virgin Voyages is partnering with Global Ports Holding, the world’s leading independent cruise port operator, to prepare for Valiant Lady’s arrival in early summer 2021.
Open for bookings December 2019, 7 night sailings start May 2021 and feature an overnight in Ibiza
The Med, home to some of the world’s best beach clubs, cultural experiences, restorative spas, yacht clubs and nightlife, is a perfect choice for Virgin Voyages. Valiant Lady will sail 3 different itineraries with truly breathtaking ports of call.
- Itinerary 1 includes the exotic delights of Barcelona, Ibiza, Monte Carlo, Marseille and Olbia
- Itinerary 2 includes a fantastic sampling of the Med featuring Barcelona, Ibiza, Toulon, Ajaccio, Marina di Carrara and Cagliari
- Itinerary 3 is a mostly Spanish immersion, stopping by Barcelona, Ibiza, Palma de Mallorca, Malaga and the British port of Gibraltar
Hearing Sailor and First Mates (travel partners) requests for later stays in ports, Virgin has delivered this on every itinerary. This means Sailors have the flexibility to make the most of their time in port and take in all that these destinations have to offer. Of particular note, every sailing features a Friday overnight stay in Ibiza, one of the most stunning and thrilling Balearic Islands. Whether it’s a blissed out beach club, a bohemian market, a serene spa, watching the stunning sunsets, or a late night out, there is no comparable place that offers the variety and style of this ultimate destination.
Introducing ‘Valiant Lady’
Virgin Voyages also revealed that the name ‘Valiant Lady’ was inspired by the Latin word valere and from the French origin, vaillant, meaning “bold”, “strong”, and “courageous." While historically, the image of women only graced the bows of ships to bring protection to a vessel, ‘Valiant Lady’ embodies the idea that women design, captain, lead and champion change in the maritime industry.
The Scarlet Lady’s sister ship ‘Valiant Lady’ will continue Virgin Voyages’ ‘Scarlet Squad’ program aimed at recruiting, supporting and mentoring female shipboard talent, and growing opportunities to access leadership roles in onboard areas such as marine, technical and hotel management that statistically show low numbers of female leadership.
All Virgin Voyages ships have been designed by a leading creative collective who are the brains behind some of the world’s most loved boutique hotel brands. The collective includes names like Design Research Studio (Tom Dixon), Roman & Williams and Concrete Amsterdam who have all been inspired by the brand’s design concept- the Modern Romance of Sailing and Mission to Redefine the Experience of a Vacation at Sea.
Future Sailors, First Mates and travel advisors are invited to check out Virgin Voyages by visiting www.virginvoyages.com or following @virginvoyages on Instagram, Facebook, Twitter or LinkedIn.
ABOUT VIRGIN VOYAGES
Virgin Voyages is a global lifestyle brand committed to creating the world’s most irresistible holidays. The brand currently has four ships on order with master shipbuilder Fincantieri and has operations in the US, UK and Europe. Virgin Voyages’ ships are designed to reflect a super yacht’s sleek luxury, featuring spaces designed by some of the top names in contemporary interiors. An Adult-by-Design sanctuary, the ships offer a dose of Vitamin Sea with well-being activated through a mix of high-energy moments coupled with relaxation and rejuvenation. Scarlet Lady will also feature never before seen entertainment and 20+ world-class intimate eateries on board. Virgin Voyages offers incredible value for its sailors with all restaurants, group fitness classes, soft drinks, and many more Virgin surprises included within the voyage fare. Scarlet Lady will sail from Miami to the Caribbean all year round from March 2020 and Valiant Lady will sail the Mediterranean from May 2021. The fleet's ships host more than 2,770 sailors and 1,160 amazing crew from around the world. Keep watch on virginvoyages.com for more updates.
FOLLOW VIRGIN VOYAGES:
Instagram: @virginvoyages
Facebook: @virginvoyages
Twitter: @virginvoyages
LinkedIn: Virgin Voyages
YouTube: Virgin Voyages
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005362/en/
Contact information
ALISON BROD MARKETING + COMMUNICATIONS
Virgin@alisonbrodmc.com
Virgin Voyages
Michelle Estevam, media@virginvoyages.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 02:35:00 EEST | Press release
Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Capability of Next Generation Earth Observation Satellites Project Title: Source-Specific CO2 Emission and Uptake Monitoring through Satellite Constellation and Ai
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom